Faron Pharmaceuticals Oy
FARN.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 103.61 | 58.35 | 217.49 |
| FCF Yield | -2.05% | -0.01% | -0.01% | -0.00% |
| EV / EBITDA | -1,553.05 | -30,235.73 | -5,414.96 | -15,715.64 |
| Quality | ||||
| ROIC | -0.06% | -0.12% | -0.07% | 1.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.54 | 1.24 | 0.60 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 63.55% | -64.25% | 24.16% | 91.13% |
| Safety | ||||
| Net Debt / EBITDA | -1,509.78 | -355.73 | 1,550.22 | -396.36 |
| Interest Coverage | -1.59 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |